Celgene signs $1bn deal to develop blood cancer therapy

31-01-2019

Celgene signs $1bn deal to develop blood cancer therapy

CIPhotos / iStockphoto.com

Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.


Celgene, Triphase Accelerator, Ontario, blood cancer, TRPH-395, collaboration

More on this story

Celgene reveals plans to acquire Juno for $9bn
23-01-2018

LSIPR